• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    mdz012.pdf
    Size:
    459.0Kb
    Format:
    PDF
    Description:
    Full text, Open Access article
    Download
    Authors
    Robson, M
    Tung, N
    Conte, P
    Im, S
    Senkus, E
    Xu, B
    Masuda, N
    Delaloge, S
    Li, W
    Armstrong, Anne C
    Wu, W
    Goessl, C
    Runswick, S
    Domchek, S
    Show allShow less
    Affiliation
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    Background: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). We now report the planned final overall survival (OS) results, and describe the most common adverse events (AEs) to better understand olaparib tolerability in this population. Patients and methods: OlympiAD, a Phase III, randomized, controlled, open-label study (NCT02000622), enrolled patients with a germline BRCAm and HER2-negative mBC who had received ?2 lines of chemotherapy for mBC. Patients were randomized to olaparib tablets (300?mg BID) or predeclared TPC (capecitabine, vinorelbine or eribulin). OS and safety were secondary endpoints. Results: 205 patients were randomized to olaparib and 97 to TPC. At 64% data maturity, median OS was 19.3 months with olaparib versus 17.1 months with TPC (HR 0.90, 95% CI 0.66-1.23; P=0.513); median follow-up was 25.3 and 26.3 months, respectively. HR for OS with olaparib vs TPC in prespecified subgroups were: prior chemotherapy for mBC (no [first-line setting]: 0.51, 95% CI 0.29-0.90); yes [second/third-line]: 1.13, 0.79-1.64); receptor status (triple negative: 0.93, 0.62-1.43; hormone receptor positive: 0.86, 0.55-1.36); prior platinum (yes: 0.83, 0.49-1.45; no: 0.91, 0.64-1.33). Adverse events during olaparib treatment were generally low grade and manageable by supportive treatment or dose modification. There was a low rate of treatment discontinuation (4.9%), and the risk of developing anemia did not increase with extended olaparib exposure. Conclusions: While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease. Olaparib was generally well-tolerated, with no evidence of cumulative toxicity during extended exposure.
    Citation
    Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Jan 23.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/621560
    DOI
    10.1093/annonc/mdz012
    PubMed ID
    30689707
    Additional Links
    https://dx.doi.org/10.1093/annonc/mdz012
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1093/annonc/mdz012
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    • Authors: Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Tung N, Armstrong A, Dymond M, Fielding A, Allen A, Conte P
    • Issue date: 2023 May
    • Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    • Authors: Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P
    • Issue date: 2019 Oct
    • Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
    • Authors: Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N
    • Issue date: 2020 May 29
    • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    • Authors: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P
    • Issue date: 2017 Aug 10
    • A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    • Authors: Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC
    • Issue date: 2016 Jun 21
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.